Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.

DMXAA (5,6-dimethylxanthenone-4-acetic acid), a novel anti-tumour agent currently undergoing clinical evaluation, appears to mediate its anti-tumour effects through immune modulation and the production of the cytokine tumour necrosis factor-alpha (TNF). Our previous studies have shown that thalidomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ching, L. M., Browne, W. L., Tchernegovski, R., Gregory, T., Baguley, B. C., Palmer, B. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063021/
https://www.ncbi.nlm.nih.gov/pubmed/9703279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063021/
https://www.ncbi.nlm.nih.gov/pubmed/9703279

Ejemplares similares